Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Pfizer Inc. is currently one of the top profitable value stocks to consider. Its forward P/E ratio of 8.66 makes it a highly attractive investment option. Pfizer's recent acquisition of Seagen has ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

The company’s ADC sigvotatug vedotin is progressing in Phase 3 trials for second-line non-small cell lung cancer, with a first-line study expected to begin in CY25. Additionally, Pfizer’s PD ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc.

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as ...